99 related articles for article (PubMed ID: 28668844)
1. The Effect of Afatinib Treatment in Non-small Cell Lung Cancer Cells.
Pancewicz-Wojtkiewicz J; Bernatowicz PL
Anticancer Res; 2017 Jul; 37(7):3543-3546. PubMed ID: 28668844
[TBL] [Abstract][Full Text] [Related]
2. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
[TBL] [Abstract][Full Text] [Related]
3. Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.
Zhang S; Zheng X; Huang H; Wu K; Wang B; Chen X; Ma S
Oncotarget; 2015 Mar; 6(8):5832-45. PubMed ID: 25714021
[TBL] [Abstract][Full Text] [Related]
4. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
5. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
Brückl W; Tufman A; Huber RM
Expert Rev Anticancer Ther; 2017 Feb; 17(2):143-155. PubMed ID: 27898252
[TBL] [Abstract][Full Text] [Related]
6. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
[TBL] [Abstract][Full Text] [Related]
7. Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.
Okamoto K; Okamoto I; Okamoto W; Tanaka K; Takezawa K; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
Cancer Res; 2010 Dec; 70(24):10402-10. PubMed ID: 21159653
[TBL] [Abstract][Full Text] [Related]
8. Clinical perspective of afatinib in non-small cell lung cancer.
Chen X; Zhu Q; Zhu L; Pei D; Liu Y; Yin Y; Schuler M; Shu Y
Lung Cancer; 2013 Aug; 81(2):155-61. PubMed ID: 23664448
[TBL] [Abstract][Full Text] [Related]
9. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
10. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Li S; Liu Z; Zhu F; Fan X; Wu X; Zhao H; Jiang L
Oncol Res; 2013; 21(3):137-44. PubMed ID: 24512728
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
[TBL] [Abstract][Full Text] [Related]
14. Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.
Chao TT; Wang CY; Chen YL; Lai CC; Chang FY; Tsai YT; Chao CH; Shiau CW; Huang YC; Yu CJ; Chen KF
Oncotarget; 2015 Feb; 6(4):2164-79. PubMed ID: 25537503
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Mukohara T; Engelman JA; Hanna NH; Yeap BY; Kobayashi S; Lindeman N; Halmos B; Pearlberg J; Tsuchihashi Z; Cantley LC; Tenen DG; Johnson BE; Jänne PA
J Natl Cancer Inst; 2005 Aug; 97(16):1185-94. PubMed ID: 16106023
[TBL] [Abstract][Full Text] [Related]
16. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
[TBL] [Abstract][Full Text] [Related]
17. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
Metro G; Crinò L
Expert Rev Anticancer Ther; 2011 May; 11(5):673-82. PubMed ID: 21554040
[TBL] [Abstract][Full Text] [Related]
18. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
[TBL] [Abstract][Full Text] [Related]
19. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Okumura S; Sasaki T; Minami Y; Ohsaki Y
J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
[TBL] [Abstract][Full Text] [Related]
20. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
